Edition:
India

Reata Announces Initiation Of Phase 1 Trial Of RTA 1701


Thursday, 21 Jun 2018 

June 20 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES INITIATION OF A PHASE 1 TRIAL OF RTA 1701, A SELECTIVE, ORAL ALLOSTERIC INHIBITOR OF RORΓT.REATA PHARMACEUTICALS INC - INITIAL RESULTS FROM RTA 1701 TRIAL ARE EXPECTED IN FIRST HALF OF 2019.REATA PHARMACEUTICALS INC - RTA 1701 DEMONSTRATED SIGNIFICANT EFFICACY AFTER ORAL DOSING IN RODENT MODELS OF RHEUMATOID ARTHRITIS & MULTIPLE SCLEROSIS. 

Company Quote

81.59
-4.4 -5.12%
14 Jun 2019